Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 3/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21347427 | 1.00 | MAPT (1.00) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL21260642 | 0.91 | KMT2A (0.83) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL4145641 | 0.90 | MAPT (0.82) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL21346962 | 0.90 | MAPT (0.81) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL21346969 | 0.88 | MAPT (0.79) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL8289821 | 0.86 | MAPT (0.76) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL21347806 | 0.84 | MAPT (0.72) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL21347385 | 0.84 | MAPT (0.72) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL4154493 | 0.83 | MAPT (0.72) | MAPTKMT2APDE4BPDE4DALDH1A1 | |
| SCHEMBL4149735 | 0.82 | MAPT (0.70) | MAPTKMT2APDE4BPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367212-A1 | PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | MATSUMOTO SHINICHI (JP) | 2025-12-04 | — | — | US | claimed |
| EP-4541372-A1 | DRUG THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | Matsumoto, Shinichi (JP) | 2025-04-23 | — | — | EP | claimed |
| CN-119384295-A | Medication of obsessive-compulsive disorder targeting dopamine D1 signaling of striatal bodies | 松本真一 | 2025-01-28 | — | — | CN | claimed |
| US-20250367212-A1 | PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | MATSUMOTO SHINICHI (JP) | 2025-12-04 | — | — | US | disclosed |
| EP-4541372-A1 | DRUG THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | Matsumoto, Shinichi (JP) | 2025-04-23 | — | — | EP | disclosed |
| CN-119384295-A | Medication of obsessive-compulsive disorder targeting dopamine D1 signaling of striatal bodies | 松本真一 | 2025-01-28 | — | — | CN | disclosed |
| WO-2023243659-A1 | DRUG THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | 松本 真一 | 2023-12-21 | — | — | WO | disclosed |
| US-20230173090-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-08 | — | — | US | disclosed |
| US-20230173090-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-08 | — | — | US | disclosed |
| US-20210040074-A1 | POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-02-11 | — | — | US | disclosed |
| WO-2019173437-A1 | POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2019-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173090-A1 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | PARK7, PRLHR, SNCA | MAPT 1080/4885KMT2A 3988/4885PDE4B 662/4885 |
| US-20210040074-A1 | POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF | CHRM1, MTNR1A, CHRNA3 | MAPT 658/4885KMT2A 3112/4885PDE4B 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.